Journal September 25, 2026 6 min read

How is the gut barrier measured?

The intestinal barrier is assessed with a small set of functional permeability probes, tight-junction and mucus protein readouts, and circulating markers of microbial translocation — each with its own model-specific cave

peptides-pro Editorial

The gut barrier is measured as intestinal permeability: the rate at which defined probe molecules cross the intestinal epithelium from lumen to blood or urine. The formal term in the literature is intestinal barrier function, and the measurement is usually called intestinal permeability; the two are used interchangeably, though barrier function also covers mucus layer thickness, antimicrobial peptide secretion, and immune sampling. There is no single identifier for the barrier itself — it is a property of a tissue, not a molecule — so the identifiers belong to the probes and markers used to interrogate it. The most common probes are lactulose, mannitol, rhamnose, cellobiose, sucralose, and polyethylene glycol (PEG) of defined molecular weight, typically PEG-400 and PEG-4000; the most common protein readouts are the tight-junction proteins occludin, zonula occludens-1 (ZO-1), and claudin family members, plus mucin 2 (MUC2) for the mucus layer. Circulating markers of translocation include lipopolysaccharide (LPS), lipopolysaccharide-binding protein (LBP), soluble CD14, and intestinal fatty acid-binding protein (I-FABP).

The work centres on the aryl hydrocarbon receptor (AHR) and Nod-like receptor pyrin domain-containing protein 6 (NLRP6) inflammasome axis in intestinal epithelial cells, alongside the wider tight-junction protein family that determines paracellular flux [6].

Research Studies

Urolithin A and AHR–NLRP6 signalling in mouse intestinal epithelial cells

In mouse intestinal epithelial cells, selective AHR activation by the microbial metabolite urolithin A (UroA) triggered the NLRP6 inflammasome and drove release of interleukin-18 (IL-18) but not IL-1β. The UroA-induced IL-18 was required for downstream IL-22, mucin 2, and related mucosal responses, linking a single metabolite to both immune signalling and barrier reinforcement [6]. This is a mechanistic study in mouse tissue; the pathway has not been shown to operate identically in humans.

Urolithin A and arsenic-induced barrier dysfunction in humanized AS3MT mice

Chronic inorganic arsenic exposure is associated with gastrointestinal disorders, and germ-free or antibiotic-treated mice show reduced fecal arsenic excretion and greater tissue accumulation. In humanized AS3MT mice — in which the mouse arsenic methyltransferase gene is replaced — UroA protected against arsenic-induced gut barrier dysfunction, extending earlier in vitro findings of protection against cytotoxicity, apoptosis, oxidative stress, and reactive oxygen species production [5]. The model is a humanized mouse, not a human trial.

Alpha-ketoglutarate and barrier protection in a mouse CKD model

Male specific-pathogen-free C57BL/6 mice were fed a control diet or a 0.25% adenine diet and given 0.9% saline or saline containing 2% alpha-ketoglutarate (AKG) for 28 days. AKG, described as having anti-inflammatory, antioxidant, and gut barrier-protective properties, was assessed for effects on chronic kidney disease and its mechanism, with transmission electron microscopy among the readouts [2]. Findings are animal-only and sex-restricted to male mice.

Oral glutamine and sex-dependent barrier responses in diet-induced obesity

Male and female C57BL/6 mice received a standard diet or a high-fat diet (60% kcal from fat) for 14 weeks; from week 12, mice received glutamine in drinking water at 2 g/kg/day or no supplementation. Body composition, glucose tolerance, insulin sensitivity, intestinal permeability, and colon outcomes were measured, and the metabolic and gut responses to oral glutamine were opposite between males and females [4]. This is a mouse study, and the sex divergence is the central finding — it should not be generalised to humans of either sex.

Yeast protein and gut barrier function during GLP-1RA-related weight loss

An ongoing clinical trial in adults with overweight or obesity receiving GLP-1 receptor agonist-related treatment for weight loss is testing whether yeast protein supplementation preserves lean body mass and muscle function. Among the secondary questions is whether supplementation affects metabolic status, inflammation, gut barrier function, gut microbiota, and related metabolites, with comparison arms of yeast protein, whey protein, and a yeast protein/whey protein blend [1]. Results are not yet reported.

Probiotic intervention and gastrointestinal outcomes in obesity during GLP-1RA treatment

GLP-1 receptor agonists — liraglutide, semaglutide, and tirzepatide — produce weight loss of approximately 9%, 15%, and 20% respectively when combined with lifestyle change, and their most common adverse events are gastrointestinal: nausea, vomiting, diarrhea, and abdominal pain, which are dose-dependent. A trial in obese patients initiating GLP-1RA treatment is evaluating a probiotic intervention for digestive health in that context [3]. The trial addresses symptoms rather than barrier permeability directly.

Postbiotic supplementation and barrier-associated symptoms in IBS

Irritable bowel syndrome is characterised by recurrent abdominal pain and altered bowel habits and is often associated with impaired intestinal barrier function, low-grade inflammation, and dysregulation of the gut-brain axis. A completed single-arm, open-label study evaluated PosBion® postbiotic supplementation in adults with IBS over 12 weeks, assessing IBS symptom severity, quality of life, gastrointestinal health, and inflammatory measures [8]. The single-arm design means no untreated comparator was included.

Microbial metabolites and the diet–microbiome–hormone axis in adolescents

A narrative review summarises research on the diet–microbiome–hormone axis in adolescents, focusing on pathways through which microbial metabolites influence host physiology. Short-chain fatty acids, microbially transformed bile acids, and postbiotic signalling molecules regulate enteroendocrine communication, insulin sensitivity, vascular function, and inflammatory tone [7]. This is a review, not primary measurement data.

Comparison of barrier measurement approaches across models

Approach	What it reads out	Model in the cited work
UroA-induced IL-18, IL-22, MUC2	Epithelial inflammasome signalling and mucus response	Mouse intestinal epithelial cells [6]
Arsenic toxicity and UroA protection	Barrier dysfunction under toxicant exposure	Humanized AS3MT mice [5]
Intestinal permeability after glutamine	Paracellular flux, sex-stratified	Male and female C57BL/6 mice, HFD [4]
Gut barrier function as secondary endpoint	Composite barrier, microbiota, metabolites	Adults on GLP-1RA-related treatment [1]
IBS symptom and inflammatory measures	Barrier-associated symptoms, not flux	Adults with IBS, single-arm [8]

Two further lines of work sit adjacent to barrier measurement without being methods papers. A systematic review following PRISMA 2020 guidelines evaluated pro-, pre-, and postbiotics for modulating the gut–adipose tissue axis in overweight dogs (body condition score ≥ 6/9) or diet-induced obesity, where luminal dysbiosis, impaired gut barrier function, and metaflammation are described as drivers [9]. A study in weaned piglets evaluated dietary curcumin-loaded mesoporous silica nanoparticles against growth, blood biochemistry, gut barrier integrity, and enteric gas emissions, in a model where weaning stress impairs barrier integrity and microbial balance [10]. A third report describes an antibacterial hyaluronic acid hydrogel with sustained release of larazotide for colitis, on the rationale that barrier loss permits pathogenic blooms while dysbiosis reduces mucus and breaks down epithelial tight junctions [11]. All three are animal or preclinical models.

If you are reading this for personal health reasons

The materials described here are sold for laboratory research only, and we do not provide dosing or medical guidance. Nothing on this page is a recommendation for any person to take any compound. If you are considering a compound for yourself, speak to a licensed clinician.